We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ion Beam Applications SA | EU:IBAB | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.34 | 2.70% | 12.92 | 12.88 | 12.96 | 13.08 | 12.68 | 12.70 | 21,689 | 13:54:36 |
Louvain-La-Neuve, Belgium, August 22, 2019 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy (PT) solutions for the treatment of cancer, today announces its consolidated results for the first half of 2019.
H1 2019 (EUR 000) | H1 2018 (EUR 000) | Variance (EUR 000) | Variance % | |
PT & Other Accelerators | 102 815 | 90 353 | +12 462 | +13.8% |
Total Net Sales | 102 815 | 90 353 | +12 462 | +13.8% |
REBITDA* | -1 546 | -3 072 | +1 526 | +49.7% |
% of Sales | -1.5% | -3.4% | ||
REBIT* | -7 118 | -6 156 | -962 | N/A |
% of Sales | -6.9% | -6.8% | ||
Profit Before Tax | -6 150 | -8 025 | +1 875 | +23.4% |
% of Sales | -6.0% | -8.9% | ||
Discontinued operations | 1 959 | 662 | +1 297 | +195.9% |
NET RESULT* | -5 317 | -7 015 | +1 698 | +24.2% |
% of Sales | -5.2% | -7.8% |
* IFRS 16 – Leases became effective on January 1, 2019. The effect of this accounting standard at June 30, 2019 is an improvement of REBIT by EUR 0.1 million and of REBITDA by EUR 1.9 million. The impact on the net result is immaterial.
Olivier Legrain, Chief Executive Officer of IBA SA, commented: “IBA experienced a strong order intake across all business lines in the first half, particularly in Other Accelerators. Three new Proton Therapy orders, and nine new orders in Other Accelerators, helped revenues increase by 13.8% from a year earlier.
“Backlog conversion in the second half of the year is due to be strong for Proton Therapy with at least six rooms expected to start installation and more than ten expected to be delivered to customers. As a result, we are reiterating full-year guidance of a positive REBIT, driven by the substantial rise in PT and Other Accelerators backlog conversion, continued growth in service revenues and a sustained focus on cost control. Dosimetry had an excellent first half in terms of both revenue growth and profitability. We continue to retain it as an asset held for sale as we actively review the most value enhancing option for its future growth and development.
“While carefully managing our costs as we seek to achieve sustained profitability, IBA is continuing to invest in R&D initiatives that will drive future growth and maintain our superior technology offering. We were particularly encouraged by progress to bring Flash irradiation to clinical treatment in the Netherlands and the UK in the first half, demonstrating IBA’s leadership in the development of this novel technique which has the potential to dramatically change the landscape of radiotherapy and patient cancer care.”
Financial highlights
million), driven by strong sales and cost controls, and REBIT up 66%. The division remains held for sale
Business highlights
***ENDS***
FULL PRESS RELEASE AVAILABLE IN ATTACHMENT
A conference call to discuss the half year results will be held today at 3pm CEST / 2pm BST / 9am EDT / 6am PDT and can be accessed online at: http://arkadinemea-events.adobeconnect.com/iba2208/event/registration.html
If you would like to participate in the Q&A, please dial (PIN code 62997065#):
Belgium: +32 2 403 58 16UK: +44 20 71 94 37 59NL: +31 207 09 51 19LU: +352 2 730 01 63US: +1 64 67 22 49 16FR: +33 1 72 72 74 03
The presentation will be available on IBA’s investor relations website and on:https://iba-worldwide.com/content/half-year-2019-results-press-release-conference-call-details-and-presentation shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Financial calendarThird Quarter Business Update November 14, 2019Full Year Results 2019 March 26, 2020
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
*Proteus®ONE and Proteus®PLUS are brand names of Proteus 235
For further information, please contact:
IBASoumya ChandramouliChief Financial Officer+32 10 475 890Investorrelations@iba-group.com
Thomas RaletVice-President Corporate Communication+32 10 475 890communication@iba-group.com
For media and investor enquiries:
Consilium Strategic CommunicationsAmber Fennell, Angela Gray, Lucy Featherstone, Lizzie Seeley+44 (0) 20 3709 5700IBA@consilium-comms.com
Attachment
1 Year Ion Beam Applications Chart |
1 Month Ion Beam Applications Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions